Holen Sie sich die Stockscreener-App
17.49
3.34%
-0.5673
Schlusskurs vom Vortag:
$18.06
Offen:
$18.39
24-Stunden-Volumen:
711.85K
Relative Volume:
0.29
Marktkapitalisierung:
$2.89B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-412.89M
KGV:
-4.5318
EPS:
-3.86
Netto-Cashflow:
$-361.93M
1W Leistung:
+17.48%
1M Leistung:
+12.34%
6M Leistung:
+32.75%
1J Leistung:
+46.95%
1-Tages-Spanne:
$17.43
$18.80
1-Wochen-Bereich:
$14.96
$20.03
52-Wochen-Spanne:
$6.36
$25.00
Dyne Therapeutics Inc Stock (DYN) Company Profile
Firmenname
Dyne Therapeutics Inc
Sektor
Branche
Telefon
(781) 786-8230
Adresse
1560 TRAPELO ROAD, WALTHAM
Compare DYN vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DYN
Dyne Therapeutics Inc
|
17.50 | 2.98B | 0 | -412.89M | -361.93M | -3.86 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.28 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
743.73 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
695.77 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.53 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.50 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-10 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-10-10 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-08-25 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2025-06-24 | Eingeleitet | Bernstein | Mkt Perform |
| 2025-06-11 | Fortgesetzt | Raymond James | Outperform |
| 2025-06-02 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-05-29 | Eingeleitet | Evercore ISI | Outperform |
| 2025-03-12 | Eingeleitet | BMO Capital Markets | Outperform |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-12-13 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-11-26 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-10-24 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-05-21 | Bestätigt | Chardan Capital Markets | Buy |
| 2024-04-30 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-02-20 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-02-27 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-02-15 | Eingeleitet | Oppenheimer | Outperform |
| 2023-01-26 | Eingeleitet | Guggenheim | Buy |
| 2022-07-20 | Eingeleitet | Chardan Capital Markets | Buy |
| 2022-07-12 | Eingeleitet | Raymond James | Outperform |
| 2020-10-12 | Eingeleitet | JP Morgan | Overweight |
| 2020-10-12 | Eingeleitet | Jefferies | Buy |
| 2020-10-12 | Eingeleitet | Piper Sandler | Overweight |
| 2020-10-12 | Eingeleitet | Stifel | Buy |
Alle ansehen
Dyne Therapeutics Inc Aktie (DYN) Neueste Nachrichten
Dyne Therapeutics launches phase 3 trial for DM1 treatment By Investing.com - Investing.com Nigeria
Dyne Therapeutics (DYN) Q4 Loss Narrows to $0.73/Share vs $0.76 Estimate, Shares Surge 11.8% - AlphaStreet
Dyne Therapeutics (DYN) Climbs 11.8% on Triple-Digit Price Target Upgrade - Finviz
Brian Posner Purchases 3,000 Shares of Dyne Therapeutics (NASDAQ:DYN) Stock - MarketBeat
Nio, Zevra Therapeutics, Vertex Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday - Benzinga
Dyne Therapeutics (DYN) Q4 Loss Narrows to $0.73/Share vs $0.76 Estimate; Shares Surge 19% - AlphaStreet
Jefferies Maintains Buy on Dyne Therapeutics (DYN) March 2026 - Meyka
Dyne Therapeutics (DYN) Receives Analyst Rating Update from Char - GuruFocus
Dyne Therapeutics (NASDAQ:DYN) Trading 11.2% HigherTime to Buy? - MarketBeat
Baird reiterates Dyne Therapeutics stock rating on trial progress By Investing.com - Investing.com Canada
Stifel reiterates Dyne Therapeutics stock rating on DMD data By Investing.com - Investing.com Australia
Dyne Therapeutics: Strong DELIVER Data Strengthens The Bull Case (NASDAQ:DYN) - Seeking Alpha
Stifel reiterates Dyne Therapeutics stock rating on trial design By Investing.com - Investing.com Canada
Jones Trading reiterates Buy on Dyne Therapeutics stock after DMD, DM1 updates - Investing.com
Stifel reiterates Dyne Therapeutics stock rating on DMD data - Investing.com South Africa
Relmada Therapeutics, Xenon Pharmaceuticals, Dianthus Therapeutics And Other Big Stocks Moving Higher On Monday - Benzinga
Dyne Therapeutics Announces Initiation of Phase 3 HARMONIA Trial of Z-Basivarsen in Myotonic Dystrophy Type 1 (DM1) - Sahm
Rate Hike: Will Dyne Therapeutics Inc benefit from government policy2026 EndofMonth & High Win Rate Trade Alerts - baoquankhu1.vn
Dyne Therapeutics Announces Initiation of Phase 3 HARMONIA Trial of Z-Basivarsen in Myotonic Dystrophy Type 1 - Investing News Network
Dyne Therapeutics (DYN) Begins Phase 3 Trial for Myotonic Dystro - GuruFocus
Dyne Therapeutics (DYN) Reveals Encouraging Results from Zelecim - GuruFocus
Dyne Therapeutics starts Phase 3 HARMONIA trial for z-basivarsen in DM1 - Traders Union
Dyne Therapeutics launches phase 3 trial for DM1 treatment - Investing.com
Dyne Therapeutics Announces New Positive Cardiopulmonary Results from DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) - Bitget
150-patient Dyne trial focuses on myotonic dystrophy daily function - Stock Titan
Dyne Therapeutics Announces New Positive Cardiopulmonary Results From Deliver Trial Of Z-Rostudirsen In Duchenne Muscular Dystrophy (Dmd) - TradingView
Dyne DMD trial shows better breathing, heart health after 24 months - Stock Titan
HC Wainwright Predicts Higher Earnings for Dyne Therapeutics - MarketBeat
A Look At Dyne Therapeutics (DYN) Valuation After Q4 2025 Earnings Beat And Ongoing Clinical Progress - Yahoo Finance
FDA curtails Pepgen’s Freedom2 operate in DM1 - bioworld.com
Lifesci Capital Brokers Raise Earnings Estimates for DYN - MarketBeat
Q1 Earnings Estimate for DYN Issued By HC Wainwright - MarketBeat
Rafferty Asset Management LLC Boosts Stake in Dyne Therapeutics, Inc. $DYN - MarketBeat
DYN: Validated platform and pipeline set stage for multiple rare disease launches and growth - TradingView
Dyne Therapeutics, Inc. $DYN Shares Acquired by Vanguard Group Inc. - MarketBeat
A Look At Dyne Therapeutics (DYN) Valuation As Late Stage Pipeline And BLA Plans Gain Momentum - simplywall.st
Morgan Stanley Maintains 'Overweight' on DYN but Lowers Price Ta - GuruFocus
Dyne Therapeutics, Inc. (DYN) Stock Analysis: A Potential 142% Upside in the Biotech Arena - DirectorsTalk Interviews
Chardan Capital Maintains Buy Rating on Dyne Therapeutics (DYN) - GuruFocus
HC Wainwright & Co. Lowers Price Target for Dyne Therapeutics (D - GuruFocus
Analysts Offer Insights on Healthcare Companies: American Well (AMWL) and Dyne Therapeutics (DYN) - The Globe and Mail
Decoding Dyne Therapeutics Inc (DYN): A Strategic SWOT Insight - GuruFocus
Chardan reiterates Dyne Therapeutics stock rating on trial data By Investing.com - Investing.com Canada
DYN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Overweight Maintained for Dyne Therapeutics (DYN) by Morgan Stanley March 2026 - Meyka
Raymond James reiterates Dyne Therapeutics stock rating on FDA pathway By Investing.com - Investing.com Canada
Dyne Therapeutics (NASDAQ:DYN) Shares Down 6.6% After Earnings Miss - MarketBeat
Morgan Stanley cuts Dyne Therapeutics stock price target on model update - Investing.com Canada
Investment Firm Adds Nearly $4 Milllion Worth of DYN Shares, According to Recent SEC Filing - The Motley Fool
Dyne’s Larger 2025 Loss And New Shelf Registration Might Change The Case For Investing In Dyne Therapeutics (DYN) - simplywall.st
Dyne Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Finanzdaten der Dyne Therapeutics Inc-Aktie (DYN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Dyne Therapeutics Inc-Aktie (DYN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Kersten Dirk | Director |
Mar 09 '26 |
Sale |
17.72 |
177,690 |
3,148,987 |
5,285,156 |
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):